Holen Sie sich die Stockscreener-App
3.29
2.08%
-0.07
Schlusskurs vom Vortag:
$3.36
Offen:
$3.45
24-Stunden-Volumen:
46,421
Relative Volume:
0.59
Marktkapitalisierung:
$30.86M
Einnahmen:
$4.02M
Nettoeinkommen (Verlust:
$-13.95M
KGV:
-0.3339
EPS:
-9.8523
Netto-Cashflow:
$-21.86M
1W Leistung:
-4.36%
1M Leistung:
-14.55%
6M Leistung:
-91.06%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.25
$3.465
1-Wochen-Bereich:
$3.25
$3.75
52-Wochen-Spanne:
$3.25
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Firmenname
Tvardi Therapeutics Inc
Sektor
Branche
Telefon
(713) 489-8654
Adresse
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
3.29 | 31.52M | 4.02M | -13.95M | -21.86M | -9.8523 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-10-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-10-13 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-13 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-14 | Eingeleitet | Raymond James | Outperform |
| 2025-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-21 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-15 | Eingeleitet | BTIG Research | Buy |
| 2024-06-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Herabstufung | Needham | Buy → Hold |
| 2024-06-13 | Herabstufung | Stifel | Buy → Hold |
| 2023-03-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Fortgesetzt | Canaccord Genuity | Buy |
| 2021-08-03 | Eingeleitet | JP Morgan | Neutral |
| 2020-04-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-29 | Bestätigt | Laidlaw | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2019-01-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2018-02-12 | Hochstufung | Janney | Neutral → Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
Alle ansehen
Tvardi Therapeutics Inc Aktie (TVRD) Neueste Nachrichten
Performance Recap: Will Tvardi Therapeutics Inc outperform during market rallies - baoquankhu1.vn
Tvardi Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | TVRD | US1407553072 - marketscreener.com
Tvardi Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | 69C | US1407553072 - marketscreener.com
Aug Swings: What hedge funds are buying Tvardi Therapeutics IncDollar Strength & Real-Time Sentiment Analysis - baoquankhu1.vn
Purchase/sale of business (net) of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView
Published on: 2026-03-12 05:56:22 - baoquankhu1.vn
Tvardi Therapeutics (TVRD) Stock Analysis Report | Financials & Insights - Benzinga Japan
What sentiment indicators say about Tvardi Therapeutics Inc. stockPortfolio Update Report & Free Community Consensus Stock Picks - Naître et grandir
Tvardi Therapeutics Sets Key Deadlines for 2026 Meeting - The Globe and Mail
Tvardi Therapeutics sets June 9, 2026 annual meeting; proxy and nomination deadlines announced - TradingView
[424B3] Tvardi Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Key deadlines for Tvardi Therapeutics (NASDAQ: TVRD) 2026 stockholder meeting - Stock Titan
Tvardi Therapeutics Inc expected to post a loss of 65 cents a shareEarnings Preview - TradingView
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Average Price Target from Brokerages - Defense World
Growth Report: Is Tvardi Therapeutics Inc attractive for institutional investorsInsider Selling & Entry Point Confirmation Alerts - baoquankhu1.vn
Tvardi Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | 0HTC | US1407553072 - marketscreener.com
CARA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Free cash flow per share of Tvardi Therapeutics Inc. – FWB:69C - TradingView
Tvardi Therapeutics, Inc. (TVRD): Investor Outlook on the Biotech Company’s 125% Potential Upside - DirectorsTalk Interviews
Analysts Are Bullish on These Healthcare Stocks: Inhibikase Therapeutics (IKT), MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
Head-To-Head Review: Tvardi Therapeutics (NASDAQ:TVRD) vs. InflaRx (NASDAQ:IFRX) - Defense World
MSN Money - MSN
Tvardi Therapeutics, Inc. (TVRD) Stock Analysis: Exploring a Potential 140% Upside in Biotechnology - DirectorsTalk Interviews
Will Tvardi Therapeutics Inc. (69C) stock sustain uptrend momentumTrade Performance Summary & Risk Managed Investment Entry Signals - mfd.ru
Will Tvardi Therapeutics Inc. outperform during market ralliesJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - mfd.ru
What is Tvardi Therapeutics Inc.’s book value per shareJuly 2025 Macro Moves & Long-Term Growth Plans - mfd.ru
Tvardi Therapeutics, Inc. (TVRD) Stock Analysis: A Look at the 129% Potential Upside in Biotech - DirectorsTalk Interviews
Published on: 2026-02-12 23:10:23 - mfd.ru
Will Tvardi Therapeutics Inc. stock maintain dividend yield2025 Price Targets & Real-Time Stock Price Movement Reports - mfd.ru
Tvardi Therapeutics to Participate in Upcoming Investor Conferences - marketscreener.com
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight - GlobeNewswire Inc.
We're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn Rate - Yahoo Finance
Tvardi Therapeutics (NASDAQ:TVRD) Rating Increased to Hold at Wall Street Zen - Defense World
Risk Report: Is BRLSW affected by consumer sentimentWeekly Gains Summary & Verified Entry Point Detection - baoquankhu1.vn
Tvardi Therapeutics (NASDAQ:TVRD) Raised to Strong-Buy at Lucid Cap Mkts - Defense World
Lucid Capital Markets upgrades Tvardi Therapeutics stock to Buy on valuation - Investing.com Nigeria
Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital - TipRanks
Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials - MSN
Growth Report: Can Tvardi Therapeutics Inc sustain its profitabilityJuly 2025 Final Week & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
What is the long term forecast for Tvardi Therapeutics Inc. stockWeekly Stock Analysis & Capital Efficient Trade Techniques - mfd.ru
MACD Signal: What is the cash position of BEEPJuly 2025 Drop Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
Is Tvardi Therapeutics (NASDAQ:TVRD) In A Good Position To Deliver On Growth Plans? - simplywall.st
Tvardi Therapeutics (NASDAQ:TVRD) Lowered to Sell Rating by Wall Street Zen - Defense World
Tvardi Therapeutics, Inc. (TVRD) Investor Outlook: Exploring an 84% Potential Upside in Innovative Biotech - DirectorsTalk Interviews
Quarterly Earnings: What hedge funds are buying Tvardi Therapeutics Inc2025 Support & Resistance & Verified Short-Term Plans - baoquankhu1.vn
New Highs: How correlated is Tvardi Therapeutics Inc to the S P500July 2025 Short Interest & Trade Opportunity Analysis Reports - baoquankhu1.vn
Tvardi Therapeutics, Inc. Updates on Clinical Trials and Pipeline Progress - TradingView
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Average Recommendation of “Hold” by Brokerages - Defense World
Why retail investors favor Tvardi Therapeutics Inc. stockQuarterly Growth Report & Low Volatility Stock Suggestions - Улправда
Will Tvardi Therapeutics Inc. (69C) stock gain from green policies2025 Technical Patterns & Expert Approved Trade Ideas - ulpravda.ru
Tvardi reports improved fibrosis scores with TTI-101 in IPF trial - Investing.com Nigeria
Finanzdaten der Tvardi Therapeutics Inc-Aktie (TVRD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):